William Blair Analysts Decrease Earnings Estimates for BMRN

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Stock analysts at William Blair lowered their Q1 2025 earnings estimates for BioMarin Pharmaceutical in a research report issued on Monday, April 14th. William Blair analyst S. Corwin now forecasts that the biotechnology company will post earnings per share of $0.77 for the quarter, down from their previous forecast of $0.85. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $3.15 per share. William Blair also issued estimates for BioMarin Pharmaceutical's FY2025 earnings at $3.47 EPS and FY2026 earnings at $4.33 EPS.

Several other research firms have also weighed in on BMRN. Cantor Fitzgerald reissued an "overweight" rating and issued a $90.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. UBS Group upped their price target on shares of BioMarin Pharmaceutical from $109.00 to $113.00 and gave the company a "buy" rating in a report on Thursday, February 20th. Scotiabank raised their price objective on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a "sector perform" rating in a research note on Thursday, February 20th. Wedbush reaffirmed an "outperform" rating and issued a $94.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Finally, Piper Sandler boosted their price target on BioMarin Pharmaceutical from $122.00 to $126.00 and gave the stock an "overweight" rating in a report on Thursday, February 20th. Seven equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $94.00.

BioMarin Pharmaceutical Stock Up 4.2 %

Shares of NASDAQ:BMRN traded up $2.46 during trading on Thursday, hitting $61.11. 476,451 shares of the company were exchanged, compared to its average volume of 1,655,021. The firm's 50 day moving average price is $66.59 and its 200-day moving average price is $66.16. BioMarin Pharmaceutical has a 12-month low of $52.93 and a 12-month high of $94.85. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.33 and a quick ratio of 2.62. The stock has a market capitalization of $11.66 billion, a P/E ratio of 27.79, a PEG ratio of 0.61 and a beta of 0.30.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, topping the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The business had revenue of $747.31 million during the quarter, compared to the consensus estimate of $711.05 million.

Insiders Place Their Bets

In related news, CAO Erin Burkhart sold 1,295 shares of the stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.52, for a total value of $92,618.40. Following the completion of the transaction, the chief accounting officer now owns 16,955 shares of the company's stock, valued at approximately $1,212,621.60. This represents a 7.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 1.85% of the stock is currently owned by company insiders.

Institutional Trading of BioMarin Pharmaceutical

Several hedge funds have recently made changes to their positions in BMRN. Merit Financial Group LLC bought a new position in BioMarin Pharmaceutical in the 4th quarter valued at about $317,000. Assenagon Asset Management S.A. boosted its position in BioMarin Pharmaceutical by 461.3% during the 4th quarter. Assenagon Asset Management S.A. now owns 611,667 shares of the biotechnology company's stock worth $40,205,000 after acquiring an additional 502,695 shares during the period. Wedmont Private Capital purchased a new stake in BioMarin Pharmaceutical in the 4th quarter worth approximately $430,000. Swedbank AB raised its stake in shares of BioMarin Pharmaceutical by 11.2% during the 4th quarter. Swedbank AB now owns 432,122 shares of the biotechnology company's stock worth $28,403,000 after purchasing an additional 43,593 shares in the last quarter. Finally, Tidal Investments LLC boosted its holdings in BioMarin Pharmaceutical by 150.4% in the third quarter. Tidal Investments LLC now owns 30,467 shares of the biotechnology company's stock worth $2,142,000 after purchasing an additional 18,300 shares in the last quarter. Institutional investors own 98.71% of the company's stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.